Effects of GLP-1 receptor agonist treatment on pulmonary function and quality of life in obese patients with chronic obstructive pulmonary disease - A prospective, randomized, placebo-controlled, double-blinded, parallel group, two-center trial for the evaluation of the effect of Liraglutide 3 mg daily on chronic obstructive pulmonary disease.

Trial Profile

Effects of GLP-1 receptor agonist treatment on pulmonary function and quality of life in obese patients with chronic obstructive pulmonary disease - A prospective, randomized, placebo-controlled, double-blinded, parallel group, two-center trial for the evaluation of the effect of Liraglutide 3 mg daily on chronic obstructive pulmonary disease.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Most Recent Events

    • 28 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top